Amyotrophic lateral sclerosis (ALS) is a fast-progressing neurodegenerative disease with an average survival time of three ...

Cells once thought passive are now seen as sculptors. Their choreography may explain how tissues form and fail. A new study ...

Researchers studied the relationship between lymphovascular invasion and adverse outcomes in patients with cutaneous squamous cell carcinoma.

What is basal cell carcinoma? Basal cell carcinoma (BCC) is the most common type of skin cancer. When found early, BCC is highly treatable. Board-certified dermatologists have expertise in diagnosing ...

This leads to extreme skin fragility as well as chronic blistering and wound formation with recurrent infections in RDEB patients, many of whom go on to develop metastatic squamous cell carcinoma ...

1Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China. 2Department of Gastrointestinal Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

Shlomo Koyfman, MD, discusses the MK-3475-630/ KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer. Shlomo Koyfman, MD, a radiation oncologist at Cleveland ...

A blood test analyzing cell-free DNA with whole-genome sequencing and machine learning demonstrated 87.4% sensitivity and 97.8% specificity for multi-cancer detection, correctly predicting tissue ...

CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal ...

Bicara Therapeutics presented data from an ongoing, 28-patient trial of its drug showing median overall survival of over 21 months, more than double that of Keytruda. CFO of the Year Join us for ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ...